Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Morgenstern

Showing results (131-140 of 179) with videos related to

Pageof 18
Sort By:
Chemical Communications (Cambridge, England)|June 29, 2011
Unprecedented incorporation of α-emitter radioisotope 213Bi into porphyrin chelates with reference to a daughter isotope mediated assistance mechanismStéphane Le Gac, Btissam Najjari, Nicolas Motreff, et al.
Cancer Letters|June 18, 2005
Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clustersYan J Song, Chang F Qu, Syed M A Rizvi, et al.
Mutagenesis|May 21, 2019
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assayHeinz H Schmeiser, Karl-Rudolf Muehlbauer, Walter Mier, et al.
Frontiers in Medicine|November 20, 2015
Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical ModelNolwenn Fichou, Sébastien Gouard, Catherine Maurel, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|June 11, 2020
Tris-{hydridotris(1-pyrazolyl)borato}actinide Complexes: Synthesis, Spectroscopy, Crystal Structure, Bonding Properties and Magnetic BehaviourChristos Apostolidis, Attila Kovács, Olaf Walter, et al.
Molecular Cancer Therapeutics|September 21, 2022
Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos CancerMagdalena Rodak, Yana Dekempeneer, Maria Wojewódzka, et al.
Nuclear Medicine Communications|December 4, 2004
Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro studyKatia Vandenbulcke, Hubert Thierens, Fritz Offner, et al.
Cancer Research|May 17, 2008
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse modelHong Song, Karineh Shahverdi, David L Huso, et al.
EJNMMI Radiopharmacy and Chemistry|March 23, 2018
Optimizing labelling conditions of <sup>213</sup>Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapyHo Sze Chan, Erik de Blois, Mark W Konijnenberg, et al.
Cancers|April 3, 2021
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft ModelMarisa Capitao, Justine Perrin, Sylvain Simon, et al.
Pageof 18

Showing results (131-140 of 179) with videos related to

Sort By:
Pageof 18
Chemical Communications (Cambridge, England)|June 29, 2011
Unprecedented incorporation of α-emitter radioisotope 213Bi into porphyrin chelates with reference to a daughter isotope mediated assistance mechanismStéphane Le Gac, Btissam Najjari, Nicolas Motreff, et al.
Cancer Letters|June 18, 2005
Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clustersYan J Song, Chang F Qu, Syed M A Rizvi, et al.
Mutagenesis|May 21, 2019
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assayHeinz H Schmeiser, Karl-Rudolf Muehlbauer, Walter Mier, et al.
Frontiers in Medicine|November 20, 2015
Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical ModelNolwenn Fichou, Sébastien Gouard, Catherine Maurel, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)|June 11, 2020
Tris-{hydridotris(1-pyrazolyl)borato}actinide Complexes: Synthesis, Spectroscopy, Crystal Structure, Bonding Properties and Magnetic BehaviourChristos Apostolidis, Attila Kovács, Olaf Walter, et al.
Molecular Cancer Therapeutics|September 21, 2022
Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos CancerMagdalena Rodak, Yana Dekempeneer, Maria Wojewódzka, et al.
Nuclear Medicine Communications|December 4, 2004
Importance of receptor density in alpha radioimmunotherapy in B cell malignancies: an in-vitro studyKatia Vandenbulcke, Hubert Thierens, Fritz Offner, et al.
Cancer Research|May 17, 2008
213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse modelHong Song, Karineh Shahverdi, David L Huso, et al.
EJNMMI Radiopharmacy and Chemistry|March 23, 2018
Optimizing labelling conditions of <sup>213</sup>Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapyHo Sze Chan, Erik de Blois, Mark W Konijnenberg, et al.
Cancers|April 3, 2021
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft ModelMarisa Capitao, Justine Perrin, Sylvain Simon, et al.
Pageof 18